Amgen Stock Price | AMGN Stock Quote, News, and History

Amgen NewsMore News

Seeking Alpha6d

J&J submits FDA application for myasthenia gravis drug nipocalimab

Seeking Alpha6d

New Medicare drug price caps could help seniors save over $1,000 a year - AARP

Zacks9d

Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know

Seeking Alpha9d

Eli Lilly, Novo Nordisk to maintain 'two horse race' in GLP-1 weight loss market

TipRanks12d

Piper Sandler Sticks to Their Buy Rating for Amgen (AMGN)

Historical Prices for Amgen

Loading..
Date	Open	Close	Daily High	Daily Low

Amgen Analyst Data

Total Analysts: 67

Buy Ratings: 35 Neutral Ratings: 24 Sell Ratings: 8

Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}

Price *Price Target

Lowest: 200.00 Median: 281.91 Highest: 355.00

*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.

Amgen Analyst Opinions

All
Buy
Hold
Sell

Date	Analyst	Rating	Price
07/11/24	Morgan Stanley	Maintained Hold	$303	neutral
06/27/24	Argus Research Company	Maintained Buy	$340	gut
06/14/24	RBC Capital Markets	Maintained Buy	$332	gut
05/09/24	Mizuho	Maintained Hold	$235	neutral
05/03/24	RBC Capital Markets	Maintained Buy	$328	gut
05/03/24	Morgan Stanley	Maintained Hold	$310	neutral
05/03/24	UBS	Maintained Hold	$307	neutral
05/03/24	William Blair	Upgraded to Buy		gut
05/03/24	BMO Capital Markets	Maintained Buy	$355	gut
05/03/24	Barclays Capital	Upgraded to Hold	$300	neutral
04/03/24	RBC Capital Markets	Maintained Buy	$329	gut
03/28/24	Raymond James Financial, Inc.	Maintained Hold		neutral
02/07/24	RBC Capital Markets	Maintained Buy	$329	gut
02/07/24	Goldman Sachs	Maintained Buy	$350	gut
02/07/24	Morgan Stanley	Maintained Hold	$278	neutral
02/01/24	Oppenheimer & Co. Inc.	Maintained Buy	$350	gut
01/29/24	UBS	Maintained Hold	$314	neutral
12/21/23	Daiwa Securities	Upgraded to Buy	$320	gut
12/19/23	BMO Capital Markets	Upgraded to Buy	$326	gut
12/12/23	RBC Capital Markets	Upgraded to Buy	$300	gut
11/09/23	Deutsche Bank	Maintained Hold	$240	neutral
11/02/23	UBS	Maintained Hold	$268	neutral
11/01/23	RBC Capital Markets	Maintained Hold	$256	neutral
11/01/23	Morgan Stanley	Maintained Hold	$291	neutral
10/25/23	Oppenheimer & Co. Inc.	Maintained Buy	$310	gut
10/20/23	Oppenheimer & Co. Inc.	Maintained Buy	$300	gut
10/20/23	J.P. Morgan	Maintained Hold	$270	neutral
10/17/23	Argus Research Company	Maintained Buy	$310	gut
10/17/23	Morgan Stanley	Maintained Hold	$300	neutral
10/12/23	Jefferies & Company Inc.	Maintained Buy	$310	gut
10/11/23	Bank of America Merrill Lynch	Maintained Hold	$290	neutral
10/09/23	Oppenheimer & Co. Inc.	Maintained Buy	$290	gut
09/18/23	Argus Research Company	Maintained Buy	$280	gut
09/06/23	HSBC	Maintained Buy	$320	gut
08/14/23	Jefferies & Company Inc.	Maintained Buy	$310	gut
08/14/23	Mizuho	Maintained Hold	$223	neutral
08/04/23	RBC Capital Markets	Maintained Hold	$253	neutral
07/25/23	Oppenheimer & Co. Inc.	Maintained Buy	$280	gut
07/12/23	Credit Suisse	Maintained Buy	$200	gut
07/11/23	Barclays Capital	Maintained Sell	$210	schlecht
06/26/23	Argus Research Company	Maintained Buy	$260	gut
05/18/23	Oppenheimer & Co. Inc.	Maintained Buy	$280	gut
05/09/23	RBC Capital Markets	Maintained Hold	$254	neutral
05/01/23	Barclays Capital	Maintained Sell	$225	schlecht
04/28/23	Piper Sandler	Maintained Buy	$288	gut
04/24/23	Oppenheimer & Co. Inc.	Maintained Buy	$290	gut
04/14/23	Barclays Capital	Maintained Sell	$227	schlecht
03/13/23	Wells Fargo & Co	Upgraded to Buy	$265	gut
02/02/23	SVB Leerink	Maintained Hold	$267	neutral
02/01/23	Wells Fargo & Co	Maintained Hold	$275	neutral

Amgen Estimates* in USD

	2024	2025	2026	2027	2028
Revenue	33,209	34,213	34,662	35,097	36,215
Dividend	9.20	9.96	10.69	11.07	12.10
Dividend Yield (in %)	2.75 %	2.98 %	3.20 %	3.32 %	3.63 %
EPS	19.53	20.85	21.43	22.10	22.94
P/E Ratio	17.09	16.01	15.57	15.11	14.56
EBIT	14,907	15,626	15,699	15,978	16,386
EBITDA	19,521	18,467	18,341	-	-
Net Profit	10,537	11,249	11,523	11,877	12,366
Net Profit Adjusted	10,537	11,249	11,523	11,877	12,366
Pre-Tax Profit	12,382	13,315	13,700	14,162	14,732
Net Profit (Adjusted)	5,008	8,057	10,531	-	-
EPS (Non-GAAP) ex. SOE	19.29	20.11	20.64	21.14	22.12
EPS (GAAP)	6.47	9.69	12.77	16.87	18.03
Gross Income	27,635	28,583	29,482	29,919	30,330
Cash Flow from Investing	-7,742	-10,526	-10,882	-10,204	-9,846
Cash Flow from Operations	12,526	13,459	14,092	15,332	15,491
Cash Flow from Financing	-7,742	-10,526	-10,882	-10,204	-9,846
Cash Flow per Share	-	23.02	26.09	-	-
Free Cash Flow	14,740	13,519	12,978	-	-
Free Cash Flow per Share	-	-	-	-	-
Book Value per Share	-	-	-	-	-
Net Debt	48,363	42,629	37,816	-	-
Research & Development Exp.	5,876	6,052	6,225	6,351	6,570
Capital Expenditure	1,232	917	1,008	795	783
Selling, General & Admin. Exp.	6,952	6,953	7,016	7,113	7,184
Shareholder’s Equity	6,668	8,991	11,125	-	-
Total Assets	96,934	95,094	95,283	92,294	100,749

	Previous Quarter ending 06/30/24	Current Quarter ending 09/30/24	Next Quarter ending 12/31/24	Current Year ending 12/31/24	Next Year ending 12/31/25
Earnings Estimates
No. of Analysts	-	20	20	23	23
Average Estimate	-	5.136 USD	5.434 USD	19.533 USD	20.845 USD
Year Ago	-	3.234 USD	1.434 USD	12.555 USD	-
Publish Date	-	10/29/2024	2/4/2025	-	-
Revenue Estimates
No. of Analysts	-	18	18	22	22
Average Estimate	-	8,516 USD	8,879 USD	33,209 USD	34,213 USD
Year Ago	-	6,870 USD	8,137 USD	28,010 USD	-
Publish Date	-	10/29/2024	2/4/2025	-	-

* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Income Statements in Mio. USD

	2023	2022	2021	2020	2019	2018	2017
Sales	28,010.00	26,092.00	25,987.00	25,246.00	23,261.00	23,768.00	22,784.00
Change of sales in %	7.35	0.40	2.94	8.53	-2.13	4.32	0.45
Gross profit on sales	19,595.00	19,686.00	19,533.00	19,087.00	18,905.00	19,667.00	18,715.00
Gross profit on sales change in %	-0.46	0.78	2.34	0.96	-3.87	5.09	1.05
Operating income	8,471.00	9,335.00	9,152.00	8,961.00	9,573.00	10,326.00	10,018.00
Operating income change in %	-9.26	2.00	2.13	-6.39	-7.29	3.07	5.19
Income before tax	7,855.00	7,346.00	6,701.00	8,133.00	9,138.00	9,545.00	9,597.00
Income before tax change in %	6.93	9.63	-17.61	-11.00	-4.26	-0.54	4.74
Income after tax	6,717.00	6,552.00	5,893.00	7,264.00	7,842.00	8,394.00	1,979.00
Income after tax change in %	2.52	11.18	-18.87	-7.37	-6.58	324.15	-74.37

Balance Sheet in Mio. USD

	2023	2022	2021	2020	2019	2018	2017
Total liabilities	90,922.00	61,460.00	54,465.00	53,539.00	50,034.00	53,916.00	54,713.00
Long-term liabilities per share	135.47	85.72	75.73	72.43	62.90	64.21	63.27
Equity	6,232.00	3,661.00	6,700.00	9,409.00	9,673.00	12,500.00	25,241.00
Equity change in %	70.23	-45.36	-28.79	-2.73	-22.62	-50.48	-15.51
Balance sheet total	97,154.00	65,121.00	61,165.00	62,948.00	59,707.00	66,416.00	79,954.00
Balance sheet total change in %	49.19	6.47	-2.83	5.43	-10.10	-16.93	3.00

Key Data in USD

	2023	2022	2021	2020	2019	2018	2017
Sales per share	52.06	48.23	45.35	42.79	38.20	35.74	31.00
P/E ratio (year end quote, basic EPS)	23.07	21.69	21.87	18.67	18.72	15.42	64.59
P/E ratio (year end quote, diluted EPS)	23.07	21.69	21.87	18.67	18.72	15.42	64.59
P/E ratio (year end quote)	23.07	21.69	21.87	18.67	18.72	15.42	64.59
Dividend yield in %	2.96	2.95	3.13	2.78	2.41	2.71	2.65
Equity ratio in %	6.41	5.62	10.95	14.95	16.20	18.82	31.57
Debt ratio in %	93.59	94.38	89.05	85.05	83.80	81.18	68.43

Amgen Insider Activity

Name	Date	shares traded	shares held	Price	type (sell/buy)	option
HOLLEY CHARLES M	08/08/2024	131.79	9,776.81	n/a	Buy	No
ISHRAK OMAR	08/08/2024	108.53	4,833.20	n/a	Buy	No
Drake Michael V	08/08/2024	108.53	3,307.30	n/a	Buy	No
Grygiel Nancy A.	07/30/2024	1,565.00	8,771.00	333.28	Sell	No
Austin Wanda M	05/30/2024	719.00	6,544.00	n/a	Buy	No
ECKERT ROBERT	05/30/2024	719.00	23,715.00	n/a	Buy	No
Garland Greg C.	05/30/2024	719.00	12,374.00	n/a	Buy	No
Jacks Tyler	05/30/2024	719.00	16,005.00	n/a	Buy	No
Grygiel Nancy A.	05/06/2024	499.00	10,300.00	n/a	Buy	No
Santos Esteban	05/06/2024	2,997.00	71,304.00	300.30	Buy	No
Griffith Peter H.	05/06/2024	3,196.00	35,973.00	n/a	Buy	No
Gordon Murdo	05/06/2024	3,529.00	52,674.00	n/a	Buy	No
REESE DAVID M	05/06/2024	3,196.00	61,889.00	n/a	Buy	No
Khosla Rachna	05/06/2024	532.00	8,559.00	n/a	Buy	No
Graham Jonathan P	05/06/2024	2,863.00	35,186.00	n/a	Buy	No
Miller Derek	05/06/2024	865.00	8,983.00	n/a	Buy	No
Drake Michael V	05/06/2024	116.55	2,455.77	n/a	Buy	No
ISHRAK OMAR	05/06/2024	116.55	3,976.67	n/a	Buy	No
HOLLEY CHARLES M	05/06/2024	141.53	8,855.02	n/a	Buy	No
Gordon Murdo	05/04/2024	665.00	49,145.00	311.29	Sell	No
Santos Esteban	05/04/2024	617.00	68,307.00	311.29	Sell	No
Grygiel Nancy A.	05/04/2024	82.00	9,801.00	311.29	Sell	No
REESE DAVID M	05/04/2024	633.00	58,693.00	311.29	Sell	No
Griffith Peter H.	05/04/2024	648.00	32,777.00	311.29	Sell	No
Busch Matthew C.	05/04/2024	27.00	4,599.00	311.29	Sell	No

Amgen Dividend Calendar

Date	Name	Dividend	*yield	Currency
2023	Amgen Inc.	8.52	2.96	USD
2022	Amgen Inc.	7.76	2.95	USD
2021	Amgen Inc.	7.04	3.13	USD
2020	Amgen Inc.	6.40	2.78	USD
2019	Amgen Inc.	5.80	2.41	USD
2018	Amgen Inc.	5.28	2.71	USD
2017	Amgen Inc.	4.60	2.65	USD
2016	Amgen Inc.	4.00	2.74	USD
2015	Amgen Inc.	3.16	1.95	USD
2014	Amgen Inc.	2.44	1.53	USD
2013	Amgen Inc.	1.88	1.65	USD
2012	Amgen Inc.	1.44	1.67	USD
2011	Amgen Inc.	0.56	0.87	USD
2010	Amgen Inc.	0.00	0.00	USD
2009	Amgen Inc.	0.00	0.00	USD
2008	Amgen Inc.	0.00	0.00	USD
2007	Amgen Inc.	0.00	0.00	USD
2006	Amgen Inc.	0.00	0.00	USD
2005	Amgen Inc.	0.00	0.00	USD
2004	Amgen Inc.	0.00	0.00	USD
2003	Amgen Inc.	0.00	0.00	USD
2002	Amgen Inc.	0.00	0.00	USD
2001	Amgen Inc.	0.00	0.00	USD
2000	Amgen Inc.	0.00	0.00	USD
1999	Amgen Inc.	0.00	0.00	USD

*Yield of the Respective Date

Amgen Inc. Calendar

Event	Estimate	Info	Date
Earnings Report	5.136 USD	Q3 2024 Earnings Release	10/29/2024
Earnings Report	5.434 USD	Q4 2024 Earnings Release	02/04/2025
Earnings Report	5.041 USD	Q1 2025 Earnings Release	05/01/2025
Earnings Report	5.509 USD	Q2 2025 Earnings Release	08/05/2025

Amgen Inc. Past Events

Event	Actual EPS	Info	Date

Amgen Profile

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr. , Franklin Pitcher Johnson, Jr. , George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Moody’s Daily Credit Risk Score

Risk

Low
Medium
High

Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’sbalance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of creditrisk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes intoaccount day-to-day movements in market value compared to a company’s liability structure.

Amgen Shareholder

Owner	in %
Freefloat	99.75
Vanguard Group, Inc. (Subfiler)	9.21
The Vanguard Group, Inc.	9.14
SSgA Funds Management, Inc.	5.51
State Street Corp.	5.40
Vanguard Total Stock Market ETF	3.15
BlackRock Fund Advisors	3.07
PRIMECAP Management Co.	2.69
Vanguard 500 Index Fund	2.60
Geode Capital Management LLC	2.24
BlackRock Institutional Trust Co. NA	2.19
Invesco QQQ Trust	1.94
Charles Schwab Investment Management, Inc.	1.92
Vanguard PRIMECAP Fund	1.68
Morgan Stanley Smith Barney LLC	1.59

Shareholder percentage totals can add to more than 100% because some holders are included in the free float.

Amgen Management

Name	Job
Robert A. Bradway	Chairman, President & Chief Executive Officer
Linda H. Louie	Chief Accounting Officer & Vice President-Finance
Matthew C. Busch	Chief Accounting Officer & Vice President-Finance
Nancy A. Grygiel	Chief Compliance Officer
Peter H. Griffith	Chief Financial Officer & Executive Vice President
Derek Miller	Chief Human Resources Officer
Mike Zahigian	Chief Information Officer & Senior Vice President
Paul Burton	Chief Medical Officer
Darryl Sleep	Chief Medical Officer & Senior VP-Global Medical
James E. Bradner	Chief Scientific Officer
David M. Reese	Chief Technology Officer & Executive VP
Mary Earley Klotman	Director
Murdo J. Gordon	EVP-Global Commercial Operations
Lori A. Johnston	Executive Vice President
Esteban Santos	Executive Vice President-Operations
Charles M. Holley	Independent Director
Brian J. Druker	Independent Director
Tyler E. Jacks	Independent Director
Wanda M. Austin	Independent Director
Amy E. Miles	Independent Director
Michael V. Drake	Independent Director
Omar Syed Ishrak	Independent Director
Ellen Jamison Kullman	Independent Director
Greg C. Garland	Independent Director
Robert A. Eckert	Lead Independent Director
Jean-Charles Soria	SVP-Research and Development
Robert T. Fremeau	Scientific Director
Li Yang	Scientific Director
Jonathan P. Graham	Secretary, Executive VP & General Counsel
Susan Sweeney	Senior VP-Global Marketing, Access & Capabilities
Mark J. Taisey	Senior VP-Global Regulatory Affairs & Strategy
Rachna Khosla	Senior Vice President-Business Development
Victoria H. Blatter	Senior Vice President-Global Government Affairs

Amgen Stock Price | AMGN Stock Quote, News, and History | Markets Insider (2024)